Close Menu
Home » Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies

Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies

Jan 28, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Dec
17
Featured Webinar

Non-Invasive Characterization of Solid Tumors via NGS Liquid Biopsy Testing

Sponsored by
Thermo Fisher Scientific

This webinar will review how liquid biopsy can be considered as an alternative and non-invasive method to tissue biopsy for cancer molecular characterization.

Dec
19
Featured Webinar

Evolution of Tumor Profiling in a Clinical Lab: Moving toward Comprehensive Genomic Profiling

Sponsored by
Qiagen

This webinar will provide a first-hand look at how a clinical lab evolved its tumor profiling workflow from a targeted panel approach toward comprehensive genomic profiling.  

Jan
28
Featured Webinar

Comprehensive Profiling of Myeloid Malignancies with Reliable Detection of FLT3 and CEBPA

Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.  

What's Popular?

In Cancer

  1. UK Study Details Liquid Biopsy's Ability to Guide Metastatic Breast Cancer Treatment

  2. ACMG Suggests Docs Evaluate All Breast Cancer Patients for Genetic Risk Test Suitability

  3. Tempus Acquires Commercial Lab, Precision Medicine Services Provider Akesogen

  4. Universal Genetic Testing in Breast Cancer May Result in More Harm Than Good, Experts Worry

    Premium

  5. New Data Emerges for Liquid Biopsy in Breast Cancer Residual Disease Detection

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.